Search Results

Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).

Momentum Biotechnologies, a leading contract research organization specializing in mass spectrometry-based native detection technologies, is pleased to announce the appointment of Harvard Medical School Professor Dr. Ying Lu to its Scientific Advisory Board.

Astellas Pharma US, Inc. (“Astellas”) announced today the company has entered into a sponsored research agreement with the UMass Chan Medical School to proceed with research for an adeno-associated virus (AAV) vector mediated gene therapy for the treatment of Alexander disease, a fatal, ultra-rare disease for which the only current treatment option is supportive care.

Vivante Health, the employee benefit for GI care, announced the addition of Dr. Hamed Khalili to its Clinical Advisory Board.

Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today reported first quarter 2024 financial results.

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

Harvard Bioscience, Inc. announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City on June 5, 2024.

The Board of Directors of the Kaiser Permanente Bernard J. Tyson School of Medicine announced the appointment of physician, educator, and women’s health expert John L. Dalrymple, MD, as the school’s new Dean and CEO after an extensive national search.